<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00914433</url>
  </required_header>
  <id_info>
    <org_study_id>TPI 1100-101</org_study_id>
    <nct_id>NCT00914433</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Inhaled TPI 1100 in Healthy Volunteers</brief_title>
  <official_title>A Phase 1,Randomized, Double--blind, Placebo-controlled Study Assessing the Safety and Tolerability, the Pharmacodynamics and Pharmacokinetics of Single-ascending and Repeated Doses of Inhaled TPI 1100 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmaxis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pharmaxis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will look at the safety and tolerability of TPI 1100 in healthy volunteers and
      look at pharmacodynamic (PD) effect on mRNA expression of PDE 4B/D &amp; 7A in blood and in
      sputum.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study was not initiated and terminated before start-up.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Drug development suspended
  </why_stopped>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Airway-specific and general safety and tolerability.</measure>
    <time_frame>24 hours post-dose and on Day 4</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect on mRNA</measure>
    <time_frame>24 hrs post-dose and on Day 4</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>TPI 1100</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug to be given by inhalation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TPI 1100</intervention_name>
    <description>1 dose only increasing dose</description>
    <arm_group_label>TPI 1100</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy, male or female volunteers aged 18 to 55 years inclusive

          -  Screening/baseline FEV1 greater than 90% predicted,

          -  Body mass index (BMI) of 19 to 28 inclusive,

          -  Clinical laboratory values and/or vital signs within normal reference ranges or not
             considered clinically significant by the Investigator

        Exclusion Criteria:

          -  Airways or systemic conditions that might affect respiratory function, including but
             not limited to clinically significant cardiac problems,

          -  Breast-feeding or pregnancy,

          -  Positive tests for smoking tobacco, alcohol, hepatitis B-surface antigen, hepatitis C
             antibody, and HIV at screening,

          -  History of serious adverse reaction to any drugs,
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pageau</last_name>
    <role>Study Director</role>
    <affiliation>Topigen Pharmaceuticals Inc.</affiliation>
  </overall_official>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 2, 2009</study_first_submitted>
  <study_first_submitted_qc>June 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2009</study_first_posted>
  <last_update_submitted>November 30, 2012</last_update_submitted>
  <last_update_submitted_qc>November 30, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

